Clinical Inertia in People with Type 2 Diabetes: a Retrospective Cohort Study of More Than 80,000 People

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2013 Jul 24

PMID 23877982

Citations 255

Authors

Kamlesh Khunti

Michael L Wolden

Brian Larsen Thorsted

Marc Andersen

Melanie J Davies

Affiliations

Soon will be listed here.

Abstract

Objective: To determine time to treatment intensification in people with type 2 diabetes treated with one, two, or three oral antidiabetes drugs (OADs) and associated levels of glycemic control.

Research Design And Methods: This was a retrospective cohort study based on 81,573 people with type 2 diabetes in the U.K. Clinical Practice Research Datalink between January 2004 and December 2006, with follow-up until April 2011.

Results: In people with HbA1c ≥7.0, ≥7.5, or ≥8.0% (≥53, ≥58, or ≥64 mmol/mol), median time from above HbA1c cutoff to intensification with an additional OAD was 2.9, 1.9, or 1.6 years, respectively, for those taking one OAD and >7.2, >7.2, and >6.9 years for those taking two OADs. Median time to intensification with insulin was >7.1, >6.1, or 6.0 years for those taking one, two, or three OADs. Mean HbA1c at intensification with an OAD or insulin for people taking one, two, or three OADs was 8.7, 9.1, and 9.7%. In patients taking one, two, or three OADs, median time from treatment initiation to intensification with an OAD or insulin exceeded the maximum follow-up time of 7.2 years. The probability of patients with poor glycemic control taking one, two, or three OADs, intensifying at end of follow-up with an OAD, was 21.1-43.6% and with insulin 5.1-12.0%.

Conclusions: There are delays in treatment intensification in people with type 2 diabetes despite suboptimal glycemic control. A substantial proportion of people remain in poor glycemic control for several years before intensification with OADs and insulin.

Citing Articles

The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.

Agur T, Steinmetz T, Goldman S, Zingerman B, Bielopolski D, Nesher E Cardiovasc Diabetol. 2025; 24(1):97.

PMID: 40022102 PMC: 11871758. DOI: 10.1186/s12933-025-02643-6.

The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.

Elnaggar M, Mansinho J, Malkin S, Whitaker J, Hunt B, Glah D Diabetes Ther. 2025; .

PMID: 39969755 DOI: 10.1007/s13300-025-01691-1.

Potential overtreatment in elderly patients with diabetes mellitus: Results from a cross-sectional study in German general practice.

Weise S, Oelschlager C, Unverzagt S, Abendroth J, Heise M, Frese T Eur J Gen Pract. 2025; 31(1):2447723.

PMID: 39964188 PMC: 11837937. DOI: 10.1080/13814788.2024.2447723.

Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes.

Nasu R, Oura T, Ohwaki K, Imori M, Furihata K Diabetes Ther. 2025; 16(3):513-526.

PMID: 39928225 PMC: 11868009. DOI: 10.1007/s13300-025-01695-x.

What Primary Care Clinicians Need to Know About Once-Weekly Insulins.

Shubrook J Fed Pract. 2025; 41(Suppl 6):S47-S52.

PMID: 39839064 PMC: 11745467. DOI: 10.12788/fp.0536.

References

Elgrably F, Costagliola D, Chwalow A, Varenne P, Slama G, TCHOBROUTSKY G . Initiation of insulin treatment after 70 years of age: patient status 2 years later. Diabet Med. 1991; 8(8):773-7. DOI: 10.1111/j.1464-5491.1991.tb01699.x. View

Ziemer D, Miller C, Rhee M, Doyle J, Watkins Jr C, Cook C . Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005; 31(4):564-71. DOI: 10.1177/0145721705279050. View

Turner R, Cull C, Frighi V, Holman R . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. DOI: 10.1001/jama.281.21.2005. View

Mulnier H, Seaman H, Raleigh V, Soedamah-Muthu S, Colhoun H, Lawrenson R . Mortality in people with type 2 diabetes in the UK. Diabet Med. 2006; 23(5):516-21. DOI: 10.1111/j.1464-5491.2006.01838.x. View

Brown J, Nichols G, Perry A . The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27(7):1535-40. DOI: 10.2337/diacare.27.7.1535. View

Khan N, Harrison S, Rose P . Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010; 60(572):e128-36. PMC: 2828861. DOI: 10.3399/bjgp10X483562. View

Ceriello A, Ihnat M, Thorpe J . Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab. 2008; 94(2):410-5. DOI: 10.1210/jc.2008-1824. View

Miccoli R, Penno G, Del Prato S . Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care. 2011; 34 Suppl 2:S231-5. PMC: 3632185. DOI: 10.2337/dc11-s235. View

Shah B, Hux J, Laupacis A, Zinman B, van Walraven C . Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?. Diabetes Care. 2005; 28(3):600-6. DOI: 10.2337/diacare.28.3.600. View

10.

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

11.

. Standards of medical care in diabetes--2012. Diabetes Care. 2011; 35 Suppl 1:S11-63. PMC: 3632172. DOI: 10.2337/dc12-s011. View

12.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6):1577-96. DOI: 10.1007/s00125-012-2534-0. View

13.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

14.

Grant R, Adams A, Trinacty C, Zhang F, Kleinman K, Soumerai S . Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007; 30(4):807-12. DOI: 10.2337/dc06-2170. View

15.

Rubino A, McQuay L, Gough S, Kvasz M, Tennis P . Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007; 24(12):1412-8. DOI: 10.1111/j.1464-5491.2007.02279.x. View

16.

Zafar A, Davies M, Azhar A, Khunti K . Clinical inertia in management of T2DM. Prim Care Diabetes. 2010; 4(4):203-7. DOI: 10.1016/j.pcd.2010.07.003. View

17.

Sreenan S, Virkamaki A, Zhang K, Hansen J . Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract. 2009; 62(12):1971-80. DOI: 10.1111/j.1742-1241.2008.01939.x. View

18.

Murray M, Harris L, Overhage J, Zhou X, Eckert G, Smith F . Failure of computerized treatment suggestions to improve health outcomes of outpatients with uncomplicated hypertension: results of a randomized controlled trial. Pharmacotherapy. 2004; 24(3):324-37. DOI: 10.1592/phco.24.4.324.33173. View

19.

Peyrot M, Rubin R, Lauritzen T, Skovlund S, Snoek F, Matthews D . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28(11):2673-9. DOI: 10.2337/diacare.28.11.2673. View

20.

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View